Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Sarcoma 39Lymphoma 38Lymphoma, Large B-Cell, Diffuse 28Lymphoma, Non-Hodgkin 22Osteosarcoma 15Burkitt Lymphoma 14Hodgkin Disease 13Testicular Neoplasms 11Recurrence 9Leukemia 9Neuroectodermal Tumors, Primitive, Peripheral 8Lymphoma, Large-Cell, Immunoblastic 8Lymphoma, Follicular 8Lymphoma, B-Cell, Marginal Zone 8Teratoma 7Ovarian Neoplasms 7Lymphoma, Mantle-Cell 7Leukemia, Lymphocytic, Chronic, B-Cell 7Testicular Germ Cell Tumor 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Neuroblastoma 6Carcinoma, Embryonal 6Breast Neoplasms 6Rhabdomyosarcoma 5Lymphoma, Large-Cell, Anaplastic 5Endodermal Sinus Tumor 5Central Nervous System Neoplasms 5Urinary Bladder Neoplasms 4Neoplasms, Germ Cell and Embryonal 4Lymphoma, B-Cell 4

Interventions

Cyclophosphamide 7fludarabine phosphate 4Tacrolimus 4Mycophenolic Acid 4Busulfan 4pembrolizumab 2fludarabine 2cobomarsen 2Whole-Body Irradiation 2Vincristine 2Rituximab 2Prednisone 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mesna 2Melphalan 2Doxorubicin 2thymoglobulin 1Vorinostat 1Plasmalyte A 1Ifosfamide 1Etoposide 1Dimethyl Sulfoxide 1Carboplatin 1Brentuximab Vedotin 1Bone Marrow Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Immune System Diseases × Ifosfamide × Clear all
NCT02592876 2019-05-17

Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma

Seagen Inc.

Phase 2 Terminated
81 enrolled 15 charts
Lymphoid

Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡